Evaxion Q1 2026 Earnings Call Summary and Key Clinical Data
Evaxion (EVAX) reported strong clinical data for its EVX-01 vaccine candidate, including a high immunogenicity rate of 86% and an overall response rate of 75%. The company also highlighted preclinical progress in glioblastoma treatment and infectious disease research. These results could positively impact investor sentiment.
Topics: AI in healthcare biotech immunotherapy vaccines